MOLN — MOLECULAR PARTNERS AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1745114 ·
Last close
$3.86
Market Cap
$147.86M
52W High
$5.36
52W Low
$3.53
ADV30
1,402
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | -13,561,000 | — | 67,930,000 | 17,154,000 |
| Mar 2026 | 0 | — | -13,443,000 | -13,144,000 | 87,658,000 | 64,251,000 | 19,206,000 |
| Dec 2025 | 0 | — | -12,667,000 | -12,649,000 | 102,107,000 | 82,653,000 | 21,773,000 |
| Sep 2025 | 0 | — | -11,930,000 | -11,836,000 | 112,150,000 | 82,359,000 | 16,621,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-48,417,000
Investing CF
$33,657,000
Financing CF
$-1,139,000
CapEx
$-714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.69
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-324,626,000
Inventory
—
Receivables
$2,313,000
ST Investments
$14,517,000
EBIT TTM
$-58,003,000
Pretax Income TTM
$-58,023,000
Interest Exp TTM
$20,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -55,436,000 | -61,651,000 | 102,107,000 | 21,773,000 | 80,334,000 | -51,257,000 |
| Dec 2024 | 4,970,000 | -61,217,000 | -54,043,000 | 158,528,000 | 16,891,000 | 141,637,000 | -59,248,000 |
| Dec 2023 | 7,038,000 | -61,108,000 | -61,984,000 | 198,352,000 | 21,923,000 | 176,429,000 | -59,005,000 |
| Dec 2022 | 189,556,000 | 116,613,000 | 117,853,000 | 262,258,000 | 27,092,000 | 235,166,000 | 118,566,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | $151.21M | $0.62 | — |
| HUMA | Humacyte, Inc. | $152.01M | $0.55 | — |
| ARMP | Armata Pharmaceuticals, Inc. | $140.55M | $3.78 | — |
| TNYA | Tenaya Therapeutics, Inc. | $132.25M | $0.59 | — |
| ENGN | enGene Therapeutics Inc. | $132.02M | $1.97 | — |
News headlines (Yahoo Finance, 1h cache)
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
2026-08-25 05:00 · Yahoo
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
2026-07-16 05:00 · Yahoo
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
2026-07-15 05:00 · Yahoo
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
2026-07-06 05:00 · Yahoo
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
2026-07-02 05:00 · Yahoo
European Penny Stocks To Watch In June 2026
2026-06-10 06:04 · Yahoo
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
2026-05-30 12:00 · Yahoo
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
2026-05-26 20:00 · Yahoo
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
2026-05-12 20:00 · Yahoo
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
2026-05-04 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.